Pacritinib Combined With Decitabine or Cytarabine in Older Patients With AML

Summary

The purpose of this study is to see if a medicine called pacritinib is both safe and effective as a study intervention for patients with AML in combination with either decitabine or cytarabine. Pacritinib is an experimental drug that is being studied to treat acute myeloid leukemia (AML). Decitabine and cytarabine are both FDA approved drugs that are used in treatment of AML. Pacritinib is being tested in clinical trials and has not been submitted to the U.S. Food and Drug Administration (FDA) for approval for any indications. Pacritinib is a drug that is designed to slow down the growth of leukemic cells.

Timeline

Start

2015-06-15

Primary completion

2016-02-09

Completion

2017-10-24

Outcome

Outcome not reported

Stopped (Business): “The study was put on clinical hold by the sponsor since Feb 9th 2016, and was later decided not to re-open due to financial constraints.”

Drugs

Indications